Cover Image
市場調查報告書

進行性多灶性白質腦病:開發中產品分析

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361634
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
進行性多灶性白質腦病:開發中產品分析 Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 31 Pages
簡介

進行性多灶性白質腦病 (PML) ,是由於JC多瘤病毒造成寡樹突膠細胞的溶解性感染疾病的腦部脫髓鞘疾病。症候有動作笨拙,進行性衰弱,視覺和表達,及有時性格改變等。危險因素,病原性的多瘤病毒,變化或衰弱的免疫系統,遺傳或環境性的要素等。

本報告提供進行性多灶性白質腦病治療藥的開發情形的相關調查,開發中產品的概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等。

簡介

  • 調查範圍

進行性多灶性白質腦病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各分子類型

進行性多灶性白質腦病的開發治療藥的企業

  • Excision BioTherapeutics Inc
  • Humabs BioMed SA
  • Neurimmune Holding AG
  • Neuway Pharma GmbH
  • Pomona Ricerca SRL

藥物簡介

暫停中的計劃

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9350IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 5 and 3 respectively.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Progressive Multifocal Leukoencephalopathy - Overview
    • Progressive Multifocal Leukoencephalopathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
    • Excision BioTherapeutics Inc
    • Humabs BioMed SA
    • Neurimmune Holding AG
    • Neuway Pharma GmbH
    • Pomona Ricerca SRL
  • Progressive Multifocal Leukoencephalopathy - Drug Profiles
    • EBT-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IKT-01427 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for JCV and BKV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPW-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNJC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Progressive Multifocal Leukoencephalopathy - Dormant Projects
  • Progressive Multifocal Leukoencephalopathy - Product Development Milestones
    • Featured News & Press Releases
      • May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy
      • Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H1 2017
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H1 2017
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H1 2017
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H1 2017
  • Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H1 2017
  • Progressive Multifocal Leukoencephalopathy - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top